BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ozekibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ozekibart\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03715933-10971@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ozekibart: Phase 1 readout est. (NCT03715933)
DESCRIPTION:ozekibart\, phase 1.\nStudy: Phase 1 Study of INBRX-109 in Subj
 ects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ozekibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03715933
URL:https://assetmemo.bio/drug/ozekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
